Analysts forecast that Horizon Therapeutics Public Limited (NASDAQ:HZNP) will report $0.91 earnings per share for the current quarter, Zacks reports. Four analysts have made estimates for Horizon Therapeutics Public’s earnings, with the highest EPS estimate coming in at $1.00 and the lowest estimate coming in at $0.86. Horizon Therapeutics Public reported earnings per share of $0.43 during the same quarter last year, which suggests a positive year-over-year growth rate of 111.6%. The firm is scheduled to report its next quarterly earnings results before the market opens on Wednesday, August 4th.
On average, analysts expect that Horizon Therapeutics Public will report full year earnings of $3.62 per share for the current financial year, with EPS estimates ranging from $3.48 to $3.82. For the next financial year, analysts forecast that the firm will post earnings of $5.18 per share, with EPS estimates ranging from $4.18 to $5.75. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow Horizon Therapeutics Public.
Horizon Therapeutics Public (NASDAQ:HZNP) last posted its quarterly earnings data on Wednesday, May 5th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.04). The company had revenue of $342.41 million during the quarter, compared to analyst estimates of $389.51 million. Horizon Therapeutics Public had a net margin of 12.81% and a return on equity of 22.28%. The company’s revenue was down 3.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.40 EPS.
Shares of NASDAQ HZNP traded up $3.66 during mid-day trading on Friday, hitting $99.83. The company’s stock had a trading volume of 35,146 shares, compared to its average volume of 1,270,820. The stock has a market capitalization of $22.44 billion, a PE ratio of 82.91, a price-to-earnings-growth ratio of 1.87 and a beta of 1.10. The company has a current ratio of 2.37, a quick ratio of 2.06 and a debt-to-equity ratio of 0.66. Horizon Therapeutics Public has a one year low of $56.20 and a one year high of $98.33. The company has a fifty day simple moving average of $93.20.
In other news, CEO Timothy P. Walbert sold 25,000 shares of the business’s stock in a transaction dated Friday, April 30th. The shares were sold at an average price of $94.98, for a total value of $2,374,500.00. Following the completion of the sale, the chief executive officer now owns 920,710 shares of the company’s stock, valued at $87,449,035.80. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Barry Moze sold 35,076 shares of the business’s stock in a transaction dated Thursday, July 8th. The shares were sold at an average price of $92.54, for a total transaction of $3,245,933.04. The disclosure for this sale can be found here. Over the last quarter, insiders sold 183,001 shares of company stock worth $16,615,912. Corporate insiders own 3.20% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. Carroll Financial Associates Inc. bought a new stake in Horizon Therapeutics Public during the first quarter worth about $36,000. Lloyd Advisory Services LLC. bought a new stake in Horizon Therapeutics Public during the first quarter worth about $46,000. AllSquare Wealth Management LLC bought a new stake in Horizon Therapeutics Public during the first quarter worth about $55,000. Bay Harbor Wealth Management LLC lifted its position in Horizon Therapeutics Public by 2,743.8% during the first quarter. Bay Harbor Wealth Management LLC now owns 910 shares of the biopharmaceutical company’s stock worth $84,000 after purchasing an additional 878 shares during the period. Finally, Fort Pitt Capital Group LLC acquired a new position in Horizon Therapeutics Public during the fourth quarter worth about $88,000. 86.01% of the stock is owned by institutional investors.
About Horizon Therapeutics Public
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.